Chemo-Free hope: new antibody tackles rare lymphoma
NCT ID NCT03322865
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests obinutuzumab, a targeted antibody, in 56 people with newly diagnosed marginal zone lymphoma who need treatment but cannot have or have failed local therapy. The goal is to see if this drug can shrink tumors without the side effects of chemotherapy. Participants receive the drug intravenously for six months, then maintenance doses if they respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Obinutuzumab (GA101)
What this could lead to
If successful, this could offer a chemotherapy-free treatment option for marginal zone lymphoma that is more effective than rituximab alone.
What could go wrong
This is a small, early-phase trial (56 participants) with no comparison group, so results may not confirm superiority. The drug may cause infusion reactions or not prevent relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta-Kranken-Anstalt gGmbH
Bochum, 44791, Germany
-
Gemeinschaftspraxis für Hämatologie und Onkologie
Münster, 48149, Germany
-
Institut für Versorgungsforschung GbR
Koblenz, 56068, Germany
-
Klinikum Passau
Passau, 94032, Germany
-
University Hospital Essen
Essen, 45147, Germany
-
University Hospital Halle
Halle, 06120, Germany
-
University Hospital Mainz
Mainz, 55101, Germany
-
University Hospital Münster
Münster, 48149, Germany
-
University Hospital Ulm
Ulm, 89081, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, 79106, Germany
-
Universitätsklinikum Mannheim
Mannheim, 68167, Germany
-
Universitätsmedizin Georg-August-University
Göttingen, 37075, Germany